Type 1 Diabetes (T1D)BEAD-T1DNCT07491471
Clinican BEAD-T1D: Building the Evidence to Address Disengagement in Type 1 Diabetes
A study testing Intervention to increase diabetes technology prescriptions in people with Type 1 Diabetes (T1D), run by Stanford University.
Trial summary
Youth with public insurance underutilize diabetes care, particularly diabetes technology which is associated with improvement in diabetes-specific outcomes. Thus, we urgently need studies to understand and increase diabetes technology utilization. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Type 1 Diabetes (T1D)
- What is being tested?
- Intervention to increase diabetes technology prescriptions
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- 15 Aug 2025to 30 Sep 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- age 18+ years, providers who care for youth with T1D for at least 50% of their clinical efforts, practicing in the United States, care for youth with public insurance, health care role of physicians, advanced practice providers, or certified diabetes care \& education specialists, and understand and willingness to follow study protocol.
Who cannot join
- significant cognitive impairment or medical or psychiatric condition that would interfere with participation in the study or lack of access to a smartphone or Wi-Fi via computer.
About this study
Official title: Improving Outcomes in Pediatric Diabetes: Building the Evidence Base to Inform Effective Diabetes Technology Interventions
Youth with public insurance underutilize diabetes care, particularly diabetes technology which is associated with improvement in diabetes-specific outcomes. Thus, we urgently need studies to understand and increase diabetes technology utilization. This proposed research will (1) address the gap in knowledge of barriers and promoters in youth working with clinicians to identify and address factors associated with diabetes technology uptake and utilization.
Read the detailed description
As diabetes technologies have become more innovative and effective in the management of pediatric type 1 diabetes (T1D), research and usage has not engaged all youth living with T1D . Studies have consistently demonstrated lower rates of diabetes technology use in some youth. Although diabetes technology has the potential to improve in pediatric T1D outcomes. This proposal aims to build an evidence base for data-driven interventions designed to increase uptake and utilization of diabetes innovations by addressing barriers and supporting promoters of diabetes technology use. Focusing on clinicians, the overall objective of this proposal is to test a brief pilot intervention to increase provider recommendation of diabetes technology.
- Conditions
- Type 1 Diabetes (T1D)
- Being tested
- Intervention to increase diabetes technology prescriptions
- Keywords
- Clinicians, Diabetes Technology
- Medical subject headings
- Diabetes Mellitus, Type 1
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intervention to increase diabetes technology prescriptionsBehavioural
The design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. We will recruit 20 clinicians to participate in the delivery of the pilot intervention.
| Study group | Role | What they receive |
|---|---|---|
| Pilot Intervention | Experimental | The design for this phase is a prospective pilot study. The intervention will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will evaluate rates of diabetes technology utilization. Virtual delivery of the pilot intervention will facilitate national recruitment. Receives: Behavioral: Intervention to increase diabetes technology prescriptions |
What is being measured
The primary outcome is the main question the study is designed to answer.
Interviews with you on your feedback on the intervention
The investigators will ask clincians questions in a 30-minute interview at the end of the four-week intervention. The investigators will evaluate feedback on ways the intervention could be more effective and what changes can be made to the intervention so that it is most effective. The investigators will ask clinicians if you they likely to change diabetes management after completing the intervention.
Measured: Within 4 weeks upon intervention completion
Survey questions on your feedback on the intervention
The investigators will ask clincians questions in a feedback survey at the end of the four-week intervention. These questions will be developed by the investigators and will ask ways the intervention could be more effective and what changes can be made to the intervention so that it is most effective. Example questions of what the investigators plan to ask in the survey include: - Was the study explained appropriately? - Was it logistically easy to participate in the study? How could it have improved? - What parts of the intervention were most helpful? - What parts could be cut? - What parts need to be added? - Are there certain types of people who are likely to do better with this intervention?
Measured: Within 4 weeks upon intervention completion
Tracking people who complete the study
The investigators will also keep track of who enrolled in the study and track how many people completed the intervention.
Measured: Through study completion, an average of one year
Secondary outcomes (1)
Changes in diabetes technology usage
The investigators will ask you survey questions to understand clinician attitudes towards diabetes technology at the start and end of the study intervention. The investigators will use a validated survey measure called Diabetes Technology Attitudes Survey to assess this in addition to having conversations with clinicians to learn beliefs about diabetes technology.
Measured: Within 4 weeks upon intervention completion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2026
- Study start15 Aug 2025 (estimated)
- Primary completion15 Sep 2026 (estimated)
- Study completion30 Sep 2026 (estimated)
Why it stopped: Change in research priority
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 1 Diabetes (T1D)Studies of the same condition, open and under way.
- More trials run by Stanford UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Stanford University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ananta Addala, Stanford University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07491471
- Sponsor's protocol ID
- 65313P
- Other IDs
- K23DK131342
- Acronym
- BEAD-T1D
- Status last verified
- Sep 2026
- First submitted
- 20 May 2025
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Outcomes in Pediatric Diabetes: Building the Evidence Base to Inform Effective Diabetes Technology Interventions
- ClinicalTrials.gov ID
- NCT07491471
- Acronym / sponsor ID
- BEAD-T1D / 65313P
- Conditions
- Type 1 Diabetes (T1D)
- Keywords
- Clinicians, Diabetes Technology
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Change in research priority
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Stanford UniversityUniversity, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study start
- 15 Aug 2025 (estimated)
- Primary completion
- 15 Sep 2026 (estimated)
- Study completion
- 30 Sep 2026 (estimated)
- First posted
- 24 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Youth with public insurance underutilize diabetes care, particularly diabetes technology which is associated with improvement in diabetes-specific outcomes. Thus, we urgently need studies to understand and increase diabetes technology utilization. This proposed research will (1) address the gap in knowledge of barriers and promoters in youth working with clinicians to identify and address factors associated with diabetes technology uptake and utilization.
Detailed description
As diabetes technologies have become more innovative and effective in the management of pediatric type 1 diabetes (T1D), research and usage has not engaged all youth living with T1D . Studies have consistently demonstrated lower rates of diabetes technology use in some youth. Although diabetes technology has the potential to improve in pediatric T1D outcomes. This proposal aims to build an evidence base for data-driven interventions designed to increase uptake and utilization of diabetes innovations by addressing barriers and supporting promoters of diabetes technology use. Focusing on clinicians, the overall objective of this proposal is to test a brief pilot intervention to increase provider recommendation of diabetes technology.
Study design
- Primary purpose
- Supportive care
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Pilot Intervention | Experimental | Behavioral: Intervention to increase diabetes technology prescriptionsThe design for this phase is a prospective pilot study. The intervention will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. The investigators will evaluate rates of diabetes technology utilization. Virtual delivery of the pilot intervention will facilitate national recruitment. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- age 18+ years, providers who care for youth with T1D for at least 50% of their clinical efforts, practicing in the United States, care for youth with public insurance, health care role of physicians, advanced practice providers, or certified diabetes care \& education specialists, and understand and willingness to follow study protocol.
Key exclusion criteria (1 listed)
- significant cognitive impairment or medical or psychiatric condition that would interfere with participation in the study or lack of access to a smartphone or Wi-Fi via computer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intervention to increase diabetes technology prescriptionsThe design for this phase is a prospective pilot study. The intervention modules will be delivered weekly over a four-week period and will include pre- and post-intervention assessments of survey measurements. We will recruit 20 clinicians to participate in the delivery of the pilot intervention. | Behavioural | Pilot Intervention |
Primary outcome
Interviews with you on your feedback on the intervention
Time frame: Within 4 weeks upon intervention completion
The investigators will ask clincians questions in a 30-minute interview at the end of the four-week intervention. The investigators will evaluate feedback on ways the intervention could be more effective and what changes can be made to the intervention so that it is most effective. The investigators will ask clinicians if you they likely to change diabetes management after completing the intervention.
Survey questions on your feedback on the intervention
Time frame: Within 4 weeks upon intervention completion
The investigators will ask clincians questions in a feedback survey at the end of the four-week intervention. These questions will be developed by the investigators and will ask ways the intervention could be more effective and what changes can be made to the intervention so that it is most effective. Example questions of what the investigators plan to ask in the survey include: - Was the study explained appropriately? - Was it logistically easy to participate in the study? How could it have improved? - What parts of the intervention were most helpful? - What parts could be cut? - What parts need to be added? - Are there certain types of people who are likely to do better with this intervention?
Tracking people who complete the study
Time frame: Through study completion, an average of one year
The investigators will also keep track of who enrolled in the study and track how many people completed the intervention.
1 secondary outcome
Changes in diabetes technology usage
Time frame: Within 4 weeks upon intervention completion
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Type 1 Diabetes (T1D)
RecruitingPhase 1
Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma
Melanoma
Active, not recruitingPhase 2
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
Metastatic Colorectal Cancer
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Active, not recruitingPhase 4
Diabetes in African Youth
type1diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study testing Intervention to increase diabetes technology prescriptions in people with Type 1 Diabetes (T1D), run by Stanford University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Interviews with you on your feedback on the intervention (time frame: Within 4 weeks upon intervention completion). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.